Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $570 from $564 and keeps an Overweight rating on the shares. Pove commentary on the Q4 call was encouraging ahead of IgAN Phase 3 interim data expected near-term, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank
- Vertex Pharmaceuticals price target lowered to $541 from $546 at RBC Capital
- Vertex Pharmaceuticals price target raised to $577 from $572 at Bernstein
- Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI
- Vertex Pharmaceuticals price target raised to $590 from $485 at Cantor Fitzgerald